HLA-A24–restricted and human telomerase reverse transcriptase peptide–specific cytotoxicity of KYO-1 and HAS-1
| Target cells . | HLA class I alleles (HLA-A*alleles) . | Peptide . | % Specific lysis* . | |||||
|---|---|---|---|---|---|---|---|---|
| KYO-1 . | HAS-1 . | |||||||
| 10:1 . | 5:1 . | 2.5:1 . | 10:1 . | 5:1 . | 2.5:1 . | |||
| Autologous LCL | KYO: A24/26, B62/−, Cw9/w4 | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2402/*2601) | TEL324 | 71.0 | 66.8 | 58.0 | 1.3 | 0 | 0 | |
| HAS: A24/33, B62/54, Cw1/w9 | TEL385 | 0 | 0 | 0 | 0 | 0 | 0 | |
| (*2402/*3303) | TEL461 | 0 | 0 | 0 | 65.4 | 52.8 | 47.4 | |
| TEL845 | 0 | 0 | 0 | 0.8 | 0 | 0 | ||
| TEL1088 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| MAGE-3 | 0 | 0 | 0 | 0.8 | 0.4 | 0 | ||
| HIV-1 gp41 | 0 | 0 | 0 | 0.6 | 0.6 | 0 | ||
| Allogeneic LCL 1 | A24/−, B52/54, Cw1/w− | None | 0 | 0 | 0 | 1.2 | 0.6 | 0 |
| (*2402/*2402) | TEL324 | 69.4 | 56.2 | 47.8 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 84.6 | 77.4 | 69.3 | ||
| Allogeneic LCL 2 | A24/2, B52/55, Cw1/w− | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2402/*0201) | TEL324 | 78.2 | 68.0 | 56.2 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 85.2 | 76.4 | 65.2 | ||
| Allogeneic LCL 3 | A26/31, B61/62, Cw3/− | None | 1.1 | 1.4 | 0.8 | 0.8 | 1.2 | 0.5 |
| (*2601/*3101) | TEL324 | 2.1 | 1.8 | 0.6 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 0.8 | 0.8 | 0.6 | ||
| Allogeneic LCL 4 | A26/33, B44/51, Cw−/− | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2601/*3303) | TEL324 | 0 | 0 | 0 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 1.5 | 0 | 0 | ||
| C1R | Negative | None | 0 | 0 | 0 | 0 | 0 | 0 |
| TEL324 | 0 | 0 | 0 | ND | ND | ND | ||
| TEL461 | ND | ND | ND | 0 | 0 | 0 | ||
| C1R-A*2402 | A24 | None | 0 | 0 | 0 | 0.4 | 0 | 0 |
| (*2402) | TEL324 | 71.7 | 59.2 | 46.0 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 55.2 | 43.2 | 37.6 | ||
| Target cells . | HLA class I alleles (HLA-A*alleles) . | Peptide . | % Specific lysis* . | |||||
|---|---|---|---|---|---|---|---|---|
| KYO-1 . | HAS-1 . | |||||||
| 10:1 . | 5:1 . | 2.5:1 . | 10:1 . | 5:1 . | 2.5:1 . | |||
| Autologous LCL | KYO: A24/26, B62/−, Cw9/w4 | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2402/*2601) | TEL324 | 71.0 | 66.8 | 58.0 | 1.3 | 0 | 0 | |
| HAS: A24/33, B62/54, Cw1/w9 | TEL385 | 0 | 0 | 0 | 0 | 0 | 0 | |
| (*2402/*3303) | TEL461 | 0 | 0 | 0 | 65.4 | 52.8 | 47.4 | |
| TEL845 | 0 | 0 | 0 | 0.8 | 0 | 0 | ||
| TEL1088 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| MAGE-3 | 0 | 0 | 0 | 0.8 | 0.4 | 0 | ||
| HIV-1 gp41 | 0 | 0 | 0 | 0.6 | 0.6 | 0 | ||
| Allogeneic LCL 1 | A24/−, B52/54, Cw1/w− | None | 0 | 0 | 0 | 1.2 | 0.6 | 0 |
| (*2402/*2402) | TEL324 | 69.4 | 56.2 | 47.8 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 84.6 | 77.4 | 69.3 | ||
| Allogeneic LCL 2 | A24/2, B52/55, Cw1/w− | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2402/*0201) | TEL324 | 78.2 | 68.0 | 56.2 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 85.2 | 76.4 | 65.2 | ||
| Allogeneic LCL 3 | A26/31, B61/62, Cw3/− | None | 1.1 | 1.4 | 0.8 | 0.8 | 1.2 | 0.5 |
| (*2601/*3101) | TEL324 | 2.1 | 1.8 | 0.6 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 0.8 | 0.8 | 0.6 | ||
| Allogeneic LCL 4 | A26/33, B44/51, Cw−/− | None | 0 | 0 | 0 | 0 | 0 | 0 |
| (*2601/*3303) | TEL324 | 0 | 0 | 0 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 1.5 | 0 | 0 | ||
| C1R | Negative | None | 0 | 0 | 0 | 0 | 0 | 0 |
| TEL324 | 0 | 0 | 0 | ND | ND | ND | ||
| TEL461 | ND | ND | ND | 0 | 0 | 0 | ||
| C1R-A*2402 | A24 | None | 0 | 0 | 0 | 0.4 | 0 | 0 |
| (*2402) | TEL324 | 71.7 | 59.2 | 46.0 | ND | ND | ND | |
| TEL461 | ND | ND | ND | 55.2 | 43.2 | 37.6 | ||
LCL indicates lymphoblastoid cell line; ND, not determined.
The cytotoxicity of KYO-1 and HAS-1 to various LCLs loaded or not loaded with the hTERT peptide was determined by 4-hour 51Cr release assays at effector:target ratios of 10:1, 5:1, and 2.5:1.